

WINNING THE WAR AGAINST CANCER



MONDAY JUNE 25, 2018

Welcome and opening remarks

The 10th Anniversary of the WIN Consortium: lessons and perspectives

John Mendelsohn, Chairman WIN Consortium, University of Texas MD Anderson Cancer Center (UT-MDACC), USA

PRESIDENTIAL SESSION 1: THE CHALLENGES OF BUILDING REAL COOPERATION TO IMPLEMENT PRECISION ONCOLOGY PROGRAMS: A LONG AND WINDING ROAD

Chair: *John Mendelsohn, UT-MDACC, USA, Chairman of WIN Consortium*

Keynote Lecture: The TAPUR family of clinical trials: building a global data sharing platform in Precision Oncology

Richard L. Schilsky, American Society of Clinical Oncology (ASCO), USA

The systems biology approach to Precision Oncology: ready to defeat cancer

Leroy Hood, Institute for Systems Biology (ISB), USA

U.S. National Cancer Institute perspective on Precision Oncology

James H. Doroshow, National Cancer Institute (NCI), USA

Beyond standard of care: the next steps of Precision Oncology - an ESMO perspective

Josep Taberero, Vall d'Hebron Institute of Oncology (VHIO), Spain. President-elect European Society for Medical Oncology (ESMO), Switzerland

Open Forum and Debate with the audience: The key issues of worldwide cooperation

- Technology and conceptual breakthroughs
- Industry or academic sponsored research
- Funding of clinical trials
- Publication policies

Moderator:

Lisa Hutchinson, Foundation for World Health (FWH) UK, WIN Consortium

Panel:

James H. Doroshow, NCI, USA

Leroy Hood, ISB, USA

John Mendelsohn, UT-MDACC, USA

Richard L. Schilsky, ASCO, USA

Josep Taberero, VHIO, Spain, ESMO

SESSION 2: THE NEXT FRONTIER OF THERAPEUTICS IN NEWLY DIAGNOSED PATIENTS: STANDARD OF CARE OR MODERN BIOMARKER DRIVEN PRECISION ONCOLOGY?

Chairs: *Razelle Kurzrock, UCSD, USA; Josep Taberero, VHIO, Spain*

A new world of early diagnosis to defeat Non-Small Cell Lung Carcinoma (NSCLC)

The WIN Consortium BOOSTER trial for identification and validation of new blood biomarkers for NSCLC

Amir Onn, Sheba Medical Center, Israel

Lessons from long-term survey of Stage I NSCLC

Harvey I. Pass, New York University, NYU Langone Health, USA

Keynote Lecture: Patients' expectations and hopes

Ellen V. Sigal, Friends of Cancer Research, USA

Newly diagnosed breast cancer at the frontier of precision oncology

Laura Esserman, University of California San Francisco (UCSF), USA

Open forum and debate with the audience: Next frontiers of therapeutics

Moderators:

Razelle Kurzrock, UCSD, USA

Josep Taberero, VHIO, Spain

Panel:

Laura Esserman, UCSF, USA

Amir Onn, Sheba Medical Center, Israel

Harvey I. Pass, NYU Langone Health, USA

Ellen V. Sigal, Friends of Cancer Research, USA

WELCOME RECEPTION, NETWORKING AND POSTER VIEWING running at the same time as

MEET THE PROFESSOR sessions to choose from:

Meeting 1: *James H. Doroshow, National Cancer Institute (NCI), USA*

Josep Taberero, Vall d'Hebron (VHIO), Spain; President-elect (ESMO), Switzerland

Meeting 2: *Richard L. Schilsky, American Society of Clinical Oncology (ASCO), USA*

John Mendelsohn, University of Texas, MD Anderson Cancer Center, USA

Meeting 3: *Ellen V. Sigal, Friends of Cancer Research, USA*

Meeting 4: *Carl H. June, Perelman School of Medicine, USA*

Laura Esserman, University of California San Francisco, USA

Meeting 5: *Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium*

ORGANIZING COMMITTEE

CHAIRS:

John Mendelsohn (USA)

Razelle Kurzrock (USA)

MEMBERS:

Lisa Hutchinson (UK)

Brian Leyland-Jones (USA)

Amir Onn (Israel)

Richard L. Schilsky (USA)

Chang-Sik Yu (South Korea)

Vladimir Lazar (France)

Catherine Bresson (France)

TUESDAY JUNE 26, 2018

SESSION 3: **DISRUPTIVE CONCEPTS AND CLINICAL TRIALS SHIFTING THE PARADIGM OF PRECISION ONCOLOGY**

Chairs: Carl H. June, Perelman School of Medicine, USA; Richard L. Schilsky, ASCO, USA

Keynote Lecture: The tri-antibody methodology for blocking the cancer cells: perspectives
Yosef Yarden, Weizmann Institute of Science, Israel

The first targeted agents tri-therapy combination trial in first therapeutic line of metastatic NSCLC: the WIN Consortium SPRING_01 trial
Razelle Kurzrock, University of California San Diego (UCSD), USA

The challenges of combining targeted therapies in biomarker driven Precision Oncology – a Pharma perspective
Jean-François Martini, Pfizer Inc., USA

MY-pathway study: when biology meets the challenges of Precision Oncology
Mary Beattie, Genentech, USA

SESSION 4: **NEW CONCEPTS AND THERAPEUTICS AVENUES IN PRECISION ONCOLOGY**

Chairs: Alan Spatz, McGill Segal Cancer Center, Canada; Elizabeth Blackburn, Salk Institute, USA

Keynote Lecture: Precision CAR T-cells therapeutics
Carl H. June, Perelman School of Medicine, USA

Importance of prevention and early interception to win the war on cancer
Elizabeth Blackburn, Salk Institute, USA

Precision Oncology approaches for immunotherapy
Eric Rubin, Merck Research Laboratories, USA

Open forum and debate with the audience: The future of drug development for Precision Oncology**Moderators:**

Elizabeth Blackburn, Salk Institute, USA
Alan Spatz, McGill Segal Cancer Centre, Canada

Panel:

Carl H. June, Perelman School of Medicine, USA
Jean-François Martini, Pfizer Inc., USA
Eric Rubin, Merck Research Laboratories, USA
Richard L. Schilsky, ASCO, USA

SESSION 5: **THE REGULATORY CHALLENGES OF A NEW MODEL OF DRUG DEVELOPMENT – THE COMBINATION OF TARGETED THERAPIES**

Chair: to be confirmed

The great hits of Precision Oncology
Bernadette Toner, GenomeWeb, USA

Access of patients to Precision Oncology
Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium

Roundtable and panel discussion**Moderators:**

To be confirmed

Panel:

Francesco De Lorenzo, ECPC, Belgium
Bernadette Toner, GenomeWeb, USA

SESSION 6: **10th YEAR OF THE WIN SYMPOSIUM IN THE ERA OF MODERN ONCOLOGY**

Chairs: Vladimir Lazar; Catherine Bresson, WIN Consortium, France

2 best posters presentations and awards10th ANNIVERSARY CEREMONY OF THE WIN SYMPOSIUM**WIN AWARDS:**

- Outstanding career
- Best speaker at WIN symposia
- Best project manager
- Best principal investigator
- Best scientific contribution
- Innovation in Precision Oncology
- Friends of WIN



10th ANNIVERSARY EVENT